Pioneering Chinese Medical Team: Intranasal Neural Stem Cell Transplantation for Parkinson’s Disease, Clinical Trial a Great Success!
**Pioneering Chinese Medical Team: Intranasal Neural Stem Cell Transplantation for Parkinson’s Disease, Clinical Trial a Great Success!**
Parkinson’s Disease
**Breakthrough Research**
The expert team at Peking Union Medical College Hospital (PUMCH) has conducted the world’s first clinical trial (ANGE-S003) using intranasal human neural stem cell transplantation to treat Parkinson’s disease, yielding promising results and offering new hope to patients!
**Study Highlights**
In this study, 18 patients with advanced Parkinson’s disease (disease duration over 5 years) received four intranasal neural stem cell transplants. The results were impressive:
**Significant Improvement in Parkinson’s Disease Rating Scale Scores**:
By the 6th month of treatment, the MDS-UPDRS score decreased by an average of 19.9 points, showing the most significant improvement (p<0.001).
**No Serious Adverse Reactions**:
Post-treatment, no serious adverse reactions related to neural stem cells were observed, and brain MRI scans showed no tumor formation.
**Limitations of Traditional Parkinson’s Disease Treatments**
Current drug and surgical treatments cannot increase the number of dopamine neurons, resulting in limited efficacy. The innovative approach of using neural stem cells aims to address this issue.
**Neural Stem Cells: A Regenerative Hope**
Parkinson’s disease involves the loss of dopamine neurons. Neural stem cells can replace these lost neurons, controlling the disease progression at its root. PUMCH’s novel method of intranasal administration of neural stem cells marks a significant milestone in Parkinson’s disease treatment.
**Future Prospects**